Seattle Startup HDT Bio Secures $1.8M U.S. Army Grant to Develop Broad-Spectrum Antiviral Nasal Spray by 2025

Seattle startup HDT Bio received a nearly $1.8 million U.S. Army grant to develop a nasal spray using proprietary RNA technology that targets a broad range of respiratory viruses, with clinical trials expected to begin in 2025. The spray aims to prevent virus replication and transmission and could be used by both military personnel and civilians.

UUniversity of Washington